Eli Lilly and Company (NYSE:LLY) Shares Purchased by FRG Family Wealth Advisors LLC

FRG Family Wealth Advisors LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,745 shares of the company’s stock after purchasing an additional 155 shares during the period. Eli Lilly and Company comprises approximately 1.1% of FRG Family Wealth Advisors LLC’s investment portfolio, making the stock its 16th biggest holding. FRG Family Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $7,918,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Tidemark LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $29,000. Core Wealth Advisors Inc. increased its position in shares of Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares in the last quarter. Lynx Investment Advisory purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $32,000. LGT Financial Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $36,000. Finally, Frank Rimerman Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $37,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on LLY shares. Berenberg Bank boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $725.00 to $1,025.00 in a research note on Monday, August 12th. Finally, Barclays increased their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $961.76.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $908.39 on Tuesday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The company has a market capitalization of $863.36 billion, a PE ratio of 133.78, a price-to-earnings-growth ratio of 2.73 and a beta of 0.42. The firm’s 50-day moving average is $895.85 and its two-hundred day moving average is $829.55. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Analysts predict that Eli Lilly and Company will post 16.51 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.57%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 15,022 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $882.47, for a total value of $13,256,464.34. Following the sale, the insider now directly owns 97,778,788 shares in the company, valued at approximately $86,286,847,046.36. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 661,900 shares of company stock valued at $604,721,602 in the last quarter. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.